Harmonia conformis

Maxx Orthopedics announces Farzin Khaghani as Chief Commercial Officer

Retrieved on: 
Tuesday, March 7, 2023
Harmonia conformis, Engineering, Queen (chess), Cornell University, Sawyer Business School, Marketing, Boston University, MS, Suffolk University, Biomedical sciences, Orthopedic surgery, Johnson & Johnson, Biology, University, Mathematics, BS, Postgraduate education, Management

NORRISTOWN, Pa., March 7, 2023 /PRNewswire-PRWeb/ -- Maxx Orthopedics, Inc., a rapidly expanding global orthopedics device company, announced today that Farzin Khaghani has joined the organization in the newly created role of Chief Commercial Officer. This will better position Maxx Orthopedics to improve and drive its strategic initiatives within the US market. Mr. Khaghani will be responsible for mobilizing the full commercial power of the organization, from sales and marketing to profit and revenue generation.

Key Points: 
  • Maxx Orthopedics, Inc., a rapidly expanding global orthopedics device company, announced today that Farzin Khaghani has joined the organization in the newly created role of Chief Commercial Officer.
  • NORRISTOWN, Pa., March 7, 2023 /PRNewswire-PRWeb/ -- Maxx Orthopedics, Inc., a rapidly expanding global orthopedics device company, announced today that Farzin Khaghani has joined the organization in the newly created role of Chief Commercial Officer.
  • This will better position Maxx Orthopedics to improve and drive its strategic initiatives within the US market.
  • Mr. Khaghani will be responsible for mobilizing the full commercial power of the organization, from sales and marketing to profit and revenue generation.

Conformis Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
Paragon, GAAP, U.S. Securities and Exchange Commission, Telephone, Health, Harmonia conformis, Company, Private Securities Litigation Reform Act, Arthralgia, Research, Translation, CFO, Coronavirus, Webcast, Risk, Annual report, Knee, Patent, ET, Marketing, Joint, Conference, Solution, CEO, Growth, Online gambling, Video game, Cryptocurrency, Bank, Internet service provider, Online shopping

Total gross profit decreased $0.4 million to $5.7 million, or 36.9% of revenue, in the first quarter of 2022, compared to $6.2 million, or 44.6% of revenue, in the first quarter of 2021.

Key Points: 
  • Total gross profit decreased $0.4 million to $5.7 million, or 36.9% of revenue, in the first quarter of 2022, compared to $6.2 million, or 44.6% of revenue, in the first quarter of 2021.
  • Weighted average basic and diluted shares outstanding of 179.2 million for the first quarter of 2022, compared to 131.3 million for the same period last year.
  • We expect our second quarter product revenue to be in the range of $14.5 million to $15.5 million.
  • In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company provides certain information regarding the Company's financial results or projected financial results on a non-GAAP "constant currency basis."

Conformis, Inc. Provides Business Update

Retrieved on: 
Monday, September 20, 2021
Partnership, Harmonia conformis, Walking, Annual report, NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Company, Growth, Pain, Identity, COVID-19, Stryker, Knee, Projection, GLOBE, Animal

Accordingly, the Company has updated its revenue outlook for the third quarter.

Key Points: 
  • Accordingly, the Company has updated its revenue outlook for the third quarter.
  • Conformis now expects product revenue for the quarter to be approximately $13.7 million to $14.3 million.
  • However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Ronald O. Royce, D.O. is recognized by Continental Who's Who

Retrieved on: 
Friday, September 17, 2021
Doctors Hospital, Continental, Harvard Medical School, Colorado Medical Society, Spirituality, Sports medicine, Osteopathic medicine in the United States, Brigham and Women's Hospital, Hospital, Surgeon, Patient, American Osteopathic Association, Boston Children's Hospital, Association, American Board of Commissioners for Foreign Missions, Hockey, Shoulder, Life, 3D, Internal fixation, Imagination, Spine, Harmonia conformis, University of North Texas Health Science Center, Dentistry

is recognized by Continental Who's Who as a Trusted Orthopedic Surgeon for his outstanding contributions in the field of Orthopedics and his professional excellence at Centura Orthopedics.

Key Points: 
  • is recognized by Continental Who's Who as a Trusted Orthopedic Surgeon for his outstanding contributions in the field of Orthopedics and his professional excellence at Centura Orthopedics.
  • As the region's largest healthcare network, Centura Orthopedics is dedicated to fulfilling the healthcare needs of those they serve.
  • Having garnered over thirty years of orthopedic experience, Dr. Ronald O. Royce specializes in shoulder and knee orthopedic surgeries.
  • Thereafter, Dr. Royce would then go on to complete his Total Joint Replacement Surgical residency at Brigham and Women's Hospital.

TANAKA Contributes to Ambix Life Science Fund, a U.S. Medical Device Venture Fund

Retrieved on: 
Monday, September 6, 2021
Finance, Academic journals, Financial markets, Ambix, Medtronic, Venture capital, Tanaka Kikinzoku

(Head office: Chiyoda-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), which is a subsidiary of TANAKA Holdings Co., Ltd. and operates the TANAKA Precious Metals manufacturing business, announced today that TANAKA made an equity contribution to Ambix Life Science Fund I, L.P., a medical device venture fund managed by Ambix Venture Management, LLC, a U.S.-based venture capital management company ("Ambix Ventures").

Key Points: 
  • (Head office: Chiyoda-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), which is a subsidiary of TANAKA Holdings Co., Ltd. and operates the TANAKA Precious Metals manufacturing business, announced today that TANAKA made an equity contribution to Ambix Life Science Fund I, L.P., a medical device venture fund managed by Ambix Venture Management, LLC, a U.S.-based venture capital management company ("Ambix Ventures").
  • TANAKA provides precious metal components and materials to medical device manufacturers and participates in development projects, cooperating with and contributing to development in the healthcare field.
  • About Ambix Life Science Fund and Aaron Berez, MD
    Ambix Life Science Fund I, L.P. is a medical device venture fund managed by Ambix Venture Management, LLC, a U.S.-based venture capital management company.
  • Overview of Ambix Life Science Fund I, L.P.
    Fund name: Ambix Life Science Fund I, L.P., a Delaware limited partnership
    The fund is a relatively new fund based around a long-standing syndicate of medical device investors.